Francisco Javier Peñalver, MD; Jose Rafael Cabrera, MD, PhD
Potential Financial Conflicts of Interest: None disclosed.
Peñalver FJ, Cabrera JR. Rituximab for Patients with Idiopathic Thrombocytopenic Purpura. Ann Intern Med. 2007;147:281. doi: 10.7326/0003-4819-147-4-200708210-00018
Download citation file:
Published: Ann Intern Med. 2007;147(4):281.
TO THE EDITOR:
We read Arnold and colleagues' systematic review (1) on the use of rituximab for idiopathic thrombocytopenic purpura (ITP) with great interest. The authors mentioned a study by our group (2) but had excluded it from their meta-analysis, claiming that our study “did not report original data.” We cannot agree with this statement, for our report certainly compiles original data, which were reported previously in abstract form only (3). Our study fulfills sufficient criteria for inclusion in the meta-analysis. Our retrospective, multicenter study assessed the therapeutic efficacy and toxicity of rituximab in 89 patients with chronic ITP that was unresponsive to several treatments. Our series is the largest reported to date on the use of rituximab in chronic ITP. It specifies the follow-up period, during which no patients were lost. In our series, a complete response was the only factor that predicted a long-held response. Response was worse in patients with longer duration of disease and in those who were heavily treated, but our results indicate that rituximab can induce good responses even in such patients and can be a good second-line therapeutic option. Rituximab induced rapid responses—most occurred in the first week after the first dose (40% of responders) and just 1 dose could be enough in some cases.
Learn more about subscription options.
Register Now for a free account.
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only